CoChat

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Open access
Zhang, Jifa, Zhang, Yinglu, Wang, Jiaxing, Xia, Yilin, Zhang, Jiaxian, Chen, Lei · 2024 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 656 of the 674 references it cites were found in a registry or an index; 285 of the 444 sources its claims cite were checked for support.

Abstract

Available drugs primarily offer symptomatic relief, while newer anti-amyloid therapies may have disease-modifying effects but still require long-term efficacy and safety validation.

Overview

CoChat Summary

TL;DR

This review synthesizes recent mechanistic, biomarker, clinical-trial, and drug-development advances in Alzheimer’s disease (AD), emphasizing that AD remains multifactorial and that no single hypothesis fully explains its progression. It highlights new FDA-approved disease-modifying antibodies and emerging drug-design strategies such as selective inhibitors, dual-target inhibitors, allosteric modulators, covalent inhibitors, PROTACs, and PPI modulators.

Key findings

  • AD is described as a complex disease involving multiple overlapping hypotheses and pathways, including cholinergic, amyloid, tau, neuroinflammation, oxidative stress, metal dyshomeostasis, glutamatergic excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy.
  • The review states that recent FDA approvals of aducanumab and lecanemab suggest potential disease-modifying effects, but their long-term efficacy and safety still need further validation.
  • For biomarker-based diagnosis, the paper reports that amyloid PET has 90% sensitivity and specificity for diagnosing AD, and that P-tau181 is the most accurate CSF indicator for distinguishing AD from non-AD dementia.
  • Traditional symptomatic drugs remain limited: AChE inhibitors and memantine can improve symptoms, but they cannot alter disease course; the paper also notes the donepezil transdermal patch (Adlarity) was FDA-approved in 2022 and showed fewer gastrointestinal adverse events than oral administration.

Methods

  • This is a narrative review of recent literature on AD mechanisms, biomarkers, clinical trials, and drug-development strategies.
  • The paper synthesizes prior findings across mechanistic hypotheses, biomarker studies, clinical-trial reports, and preclinical/early-stage drug examples rather than presenting a new dataset.
  • Its analysis is primarily descriptive and integrative, organizing the field by disease mechanism, diagnostic approach, and therapeutic modality.

Limitations

  • The paper states that no unified theory explains AD and that the interplay among pathological aspects requires further elucidation and validation.
  • It notes that the high failure rate of clinical trials limits validation of hypotheses and that the long-term efficacy and safety of newer drugs such as aducanumab and lecanemab still need further study.
  • Evident from the text: much of the drug-development discussion is based on preclinical studies, animal models, or early-phase trials, so many proposed strategies remain unconfirmed in larger human studies.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01911-3

Cites

656 of 656 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Diagram for the pathogenesis of AD, including the cholinergic hypothesis,619,620 the glutamatergic hypothesis,621 the amyloid hypothesis,622,623 the tau protein hypothesis,624,625 the inflammatory hypothesis,626,627 the microbiota-gut-brain axis hypothesis,628,629 the oxidative stress hypothesis,191 the metal ion hypothesis,630,631 and the abnormal autophagy hypothesis235
Fig. 1 Diagram for the pathogenesis of AD, including the cholinergic hypothesis,619,620 the glutamatergic hypothesis,621 the amyloid hypothesis,622,623 the tau protein hypothesis,624,625 the inflammatory hypothesis,626,627 the microbiota-gut-brain axis hypothesis,628,629 the oxidative stress hypothesis,191 the metal ion hypothesis,630,631 and the abnormal autophagy hypothesis235CC BY · PubMed Central
Fig. 2 Schematic illustration depicting the possible molecular downstream pathways of Aβ on neuronal synapses and astrocytes. (1) Aβ is capable of interacting with cell membranes and binding to a variety of synaptic receptors such as PrPC, NMDA receptors, P75NTR, and mGluR5, which leads to a cascade of events including calcium dyshomeostasis, inhibition of long-term potentiation (LTP), tau hyperphosphorylation, mitochondrial dysfunction, and oxidative stress, ultimately resulting in neuronal death.112,632,633 (2) Aβ blocks the reuptake of glutamate by excitatory amino acid transporter (EAAT) receptors, causing glutamate accumulation intersynaptically and neuronal hyperactivity.634 (3) Aβ and some pro-inflammatory cytokines (such as TNFα, IL-1α, and C1q) may induce the A1 phenotype of astrocytes. This transformation may involve altering astrocyte functions and modulating their interactions with other cells (such as neurons and microglia), thereby participating in processes such as Aβ deposition, neuroinflammation, synaptic loss, and neuronal death.635–637 (4) APOE, primarily released from astrocytes, associates with lipoproteins to form APOE-associated lipoprotein particles, which can bind to soluble Aβ and mediate its clearance119
Fig. 2 Schematic illustration depicting the possible molecular downstream pathways of Aβ on neuronal synapses and astrocytes. (1) Aβ is capable of interacting with cell membranes and binding to a variety of synaptic receptors such as PrPC, NMDA receptors, P75NTR, and mGluR5, which leads to a cascade of events including calcium dyshomeostasis, inhibition of long-term potentiation (LTP), tau hyperphosphorylation, mitochondrial dysfunction, and oxidative stress, ultimately resulting in neuronal death.112,632,633 (2) Aβ blocks the reuptake of glutamate by excitatory amino acid transporter (EAAT) receptors, causing glutamate accumulation intersynaptically and neuronal hyperactivity.634 (3) Aβ and some pro-inflammatory cytokines (such as TNFα, IL-1α, and C1q) may induce the A1 phenotype of astrocytes. This transformation may involve altering astrocyte functions and modulating their interactions with other cells (such as neurons and microglia), thereby participating in processes such as Aβ deposition, neuroinflammation, synaptic loss, and neuronal death.635–637 (4) APOE, primarily released from astrocytes, associates with lipoproteins to form APOE-associated lipoprotein particles, which can bind to soluble Aβ and mediate its clearance119CC BY · PubMed Central
Fig. 3 Schematic illustration depicting potential molecular downstream pathways of Aβ on microglia. Microglia has numerous pattern recognition receptors that can bind to Aβ, initiating an inflammatory cascade. This process promotes the assembly and activation of NLRP3, leading to the release of pro-inflammatory cytokines, which further exacerbate the aggregation of Aβ.171 In addition, the diagram also encompasses the downstream signaling pathways of TREM2.638,639 Some variants associated with AD, such as the TREM2 variant R47H, may potentially diminish the binding or internalization of TREM2 with ligands such as APOE-Aβ complexes, APOE, phospholipids, and Aβ. This reduction may consequently impair the activation of microglial cells, thereby compromising their ability to clear amyloid plaques.638,640–643 It is worth noting that there remain many uncertainties and controversies regarding the in vivo ligands and signaling pathways of TREM2, as well as the relationship between TREM2 variants and AD. Future in vivo experiments are needed to elucidate these aspects
Fig. 3 Schematic illustration depicting potential molecular downstream pathways of Aβ on microglia. Microglia has numerous pattern recognition receptors that can bind to Aβ, initiating an inflammatory cascade. This process promotes the assembly and activation of NLRP3, leading to the release of pro-inflammatory cytokines, which further exacerbate the aggregation of Aβ.171 In addition, the diagram also encompasses the downstream signaling pathways of TREM2.638,639 Some variants associated with AD, such as the TREM2 variant R47H, may potentially diminish the binding or internalization of TREM2 with ligands such as APOE-Aβ complexes, APOE, phospholipids, and Aβ. This reduction may consequently impair the activation of microglial cells, thereby compromising their ability to clear amyloid plaques.638,640–643 It is worth noting that there remain many uncertainties and controversies regarding the in vivo ligands and signaling pathways of TREM2, as well as the relationship between TREM2 variants and AD. Future in vivo experiments are needed to elucidate these aspectsCC BY · PubMed Central
Fig. 4 Signaling pathways linked to AD pathogenesis. a Neuroinflammatory signaling. It involves interactions among various cell types, which influence neuroinflammation by activating multiple pathways. This leads to the production of inflammatory mediators and neuronal damage, accelerating the pathological progression of AD. b Lysosomal dysfunction. It may be related to impairments in V-ATPase-mediated lysosomal acidification and/or dysregulation of lysosomal calcium homeostasis. However, the specific mechanisms require further investigation to be definitively determined. c Aberrant cholesterol metabolism. d Mitochondrial dysfunction. Mitochondria in AD are damaged in various ways, including impairments in oxidative phosphorylation, calcium homeostasis, mtDNA, mitochondrial fusion and fission, axonal transport, and mitophagy. These dysfunctions lead to impaired energy production and increased oxidative stress.283 e Calcium signaling in AD. Under physiological conditions, calcium ions follow a strict concentration gradient. In AD, the elevated cytosolic calcium concentration and calcium-responsive signaling cascades adversely affect protein folding in the ER, energy production in mitochondria, and lysosomal acidity.307 g Insulin signaling in AD. f Dysregulated neurotrophic signaling pathway. h BBB dysfunction. The disruption of the integrity and alterations in the transport functions of BBB lead to the abnormal entry and exit of certain substances into and out of brain tissue, resulting in neuronal damage and further exacerbating the pathological progression of AD644
Fig. 4 Signaling pathways linked to AD pathogenesis. a Neuroinflammatory signaling. It involves interactions among various cell types, which influence neuroinflammation by activating multiple pathways. This leads to the production of inflammatory mediators and neuronal damage, accelerating the pathological progression of AD. b Lysosomal dysfunction. It may be related to impairments in V-ATPase-mediated lysosomal acidification and/or dysregulation of lysosomal calcium homeostasis. However, the specific mechanisms require further investigation to be definitively determined. c Aberrant cholesterol metabolism. d Mitochondrial dysfunction. Mitochondria in AD are damaged in various ways, including impairments in oxidative phosphorylation, calcium homeostasis, mtDNA, mitochondrial fusion and fission, axonal transport, and mitophagy. These dysfunctions lead to impaired energy production and increased oxidative stress.283 e Calcium signaling in AD. Under physiological conditions, calcium ions follow a strict concentration gradient. In AD, the elevated cytosolic calcium concentration and calcium-responsive signaling cascades adversely affect protein folding in the ER, energy production in mitochondria, and lysosomal acidity.307 g Insulin signaling in AD. f Dysregulated neurotrophic signaling pathway. h BBB dysfunction. The disruption of the integrity and alterations in the transport functions of BBB lead to the abnormal entry and exit of certain substances into and out of brain tissue, resulting in neuronal damage and further exacerbating the pathological progression of AD644CC BY · PubMed Central
Fig. 5 Approved drugs for AD by FDA/China. Notably, the definition of disease-modifying therapies, capable of producing enduring and impactful changes in the clinical progression of AD, was first proposed in 2017.412 (The numbers 1, 2,…… 8, 9 in the figure represent the drug identifiers defined by the authors)
Fig. 5 Approved drugs for AD by FDA/China. Notably, the definition of disease-modifying therapies, capable of producing enduring and impactful changes in the clinical progression of AD, was first proposed in 2017.412 (The numbers 1, 2,…… 8, 9 in the figure represent the drug identifiers defined by the authors)CC BY · PubMed Central
Fig. 6 a Chemical structures of selective inhibitors 32-44. b Dual-target inhibitors 45-50. c GSK-3 degrader 62, as well as PhosTACs 63 and 64. (The numbers 32, 33,…… 51, 62, 63, 64 in the figure represent the compound identifiers defined by the authors)
Fig. 6 a Chemical structures of selective inhibitors 32-44. b Dual-target inhibitors 45-50. c GSK-3 degrader 62, as well as PhosTACs 63 and 64. (The numbers 32, 33,…… 51, 62, 63, 64 in the figure represent the compound identifiers defined by the authors)CC BY · PubMed Central
Fig. 7 a Chemical structures and modification schemes of allosteric modulators 52-57. b covalent inhibitors 59-61. c Compounds 65-74 target the PPI network. (The numbers 52, 53,…… 57, 59, 60, 61, 65,…… 74 in the figure represent the compound identifiers defined by the authors)
Fig. 7 a Chemical structures and modification schemes of allosteric modulators 52-57. b covalent inhibitors 59-61. c Compounds 65-74 target the PPI network. (The numbers 52, 53,…… 57, 59, 60, 61, 65,…… 74 in the figure represent the compound identifiers defined by the authors)CC BY · PubMed Central

Verification

Claims the paper makes

187 Valid · 4 Not valid · 68 Not checked · 29 Own results and interpretations

123 more claims · 79 with their cited sources checked

Create a free account to see all 288 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 135
  • Probably not a substantial claim. 31

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Items 201–400 of 656

Research works printed but not linked: 3

  1. Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567–S610 (2018). 29843241 10.3233/JAD-179941 PMC6004937 · DOI · Paper page
  2. Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δ Inhibitors. ACS Med. Chem. Lett. 11, 1168–1174 (2020). 32550997 10.1021/acsmedchemlett.0c00028 PMC7294733 · DOI · Paper page
  3. Zhang, Y. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023). 37386015 10.1038/s41392-023-01484-7 PMC10310781 · DOI · Paper page

Cited by

See all 1,144

Metadata

Authors
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L.
Affiliations
  • Sichuan University (CN)
  • University of Tennessee Health Science Center (US)
Corresponding author
Chen, Lei
Venue
Signal Transduction and Targeted Therapy
Published
2024-08-23
Volume
9
Issue
1
Pages
211-211
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4401806028
Cited by
1,138
References
674
Citations by year
2026: 516 · 2025: 588 · 2024: 32
FWCI
335.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
Keywords
Alzheimer's disease, Alzheimer's disease pathogenesis, amyloid hypothesis, tau protein, cholinergic hypothesis, neuroinflammation, oxidative stress, microbiota-gut-brain axis
MeSH terms
Drug Development, Alzheimer Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.